Copyright: ©Author(s) 2026.
World J Psychiatry. Nov 19, 2026; 16(11): 125243
Published online Nov 19, 2026. doi: 10.5498/wjp.125243
Published online Nov 19, 2026. doi: 10.5498/wjp.125243
Table 3 Clinical applicability, advantages, limitations, and current evidence status of interventions for post-stroke mood-sleep-circadian dysregulation
| Intervention | Main target population or indication | Main advantages | Major limitations and implementation issues | Current evidence and clinical status |
| Basic sleep and circadian care | Stroke patients receiving acute or inpatient rehabilitation care, particularly those with environmental sleep disruption or a weakened day-night rhythm | Low risk, inexpensive, and feasible within routine multidisciplinary care | Effects on mood and functional recovery are difficult to isolate; implementation depends on ward organization and staff coordination | Routine supportive care consistent with rehabilitation guidelines, although direct intervention evidence for mood outcomes remains limited[32,33] |
| Stroke-adapted CBT-I | Medically stable patients with an insomnia-dominant phenotype; caregiver support may be required when communication or cognitive limitations are present | First-line nonpharmacological treatment for chronic insomnia; avoids sedative adverse effects and addresses behavioral factors that maintain insomnia | Requires trained personnel and adaptation for aphasia, cognitive impairment, or severe fatigue; treatment engagement may be difficult | Established for chronic insomnia in adults; clinically reasonable after stroke, but stroke-specific evidence remains limited[34] |
| Continuous positive airway pressure | Patients with confirmed sleep apnea, particularly those with snoring, witnessed apnea, or persistent daytime sleepiness | Directly treats airway obstruction and intermittent hypoxia; may support vascular and neurological recovery | Adherence and mask tolerance remain major barriers; cognitive or physical impairment may complicate treatment; direct effects on mood remain uncertain | Established treatment for confirmed sleep apnea; evidence for post-stroke recovery is supportive but heterogeneous[35] |
| Morning bright light and circadian scheduling | Patients with circadian disruption, excessive daytime napping, low daytime activity, or irregular sleep-wake timing | Low pharmacological burden and directly strengthens environmental timing cues; feasible during rehabilitation | Optimal light intensity, timing, and treatment duration remain uncertain; response may vary among patients | Promising but still exploratory as a stroke-specific intervention; evidence is based on a limited number of clinical trials[36] |
| Exercise and structured daytime activity | Medically stable patients with reduced activity, physical deconditioning, fatigue, or depressive symptoms | Already forms part of routine rehabilitation and may support mood, sleep, and functional recovery | Intensity must be adapted to neurological and cardiovascular status; intervention protocols remain heterogeneous | Routine rehabilitation component with supportive evidence for reducing depressive symptoms[39] |
| Antidepressant medication and structured psychotherapy | Patients with clinically significant or persistent post-stroke depression or anxiety | Directly targets emotional symptoms and can be integrated with rehabilitation and sleep-focused care | Medication adverse effects and interactions require monitoring; psychotherapy may be limited by aphasia, cognitive impairment, or access to trained professionals | Established components of post-stroke depression care; evidence is stronger for depression than for post-stroke anxiety[37] |
| Repetitive transcranial magnetic stimulation | Selected medically stable patients with persistent post-stroke depression, particularly when standard treatment is insufficient or poorly tolerated | Nonpharmacological neuromodulation with potential antidepressant effects | Requires specialized equipment and trained personnel; treatment protocols remain heterogeneous; accessibility and cost may limit use | Specialized adjunct rather than routine first-line treatment; supported by meta-analytic evidence but requiring further protocol standardization[38] |
| Anti-inflammatory pharmacotherapy | No established routine indication for post-stroke depression or anxiety; currently relevant mainly to research settings | Biologically plausible and may target pathways implicated in the proposed network | Clinical efficacy, appropriate patient selection, and safety remain uncertain; inflammatory biomarkers are nonspecific | Exploratory; anti-inflammatory medication cannot currently be recommended specifically for post-stroke depression or anxiety outside clinical research |
| Melatonin and other chronobiotic strategies | Selected patients with circadian misalignment or persistent sleep-timing disturbance | May support circadian timing with a relatively low treatment burden | Stroke-specific efficacy and optimal timing remain uncertain; medication interactions and individual tolerability require consideration | Exploratory in post-stroke care and not yet supported for routine phenotype-based use |
| Sedative or hypnotic medication | Selected patients with severe short-term sleep disturbance when nonpharmacological measures are insufficient | May provide short-term symptom relief | Sedation, falls, cognitive adverse effects, respiratory suppression, and daytime impairment are important concerns after stroke | Selective and cautious use only; not preferred as the sole or first-line long-term strategy |
- Citation: Liu XA, Liu J, Xu D, Zhao X. Inflammation, sleep-circadian disruption, and neuropsychiatric recovery after stroke: Mechanisms and integrated interventions for post-stroke depression and anxiety. World J Psychiatry 2026; 16(11): 125243
- URL: https://www.wjgnet.com/2220-3206/full/v16/i11/125243.htm
- DOI: https://dx.doi.org/10.5498/wjp.125243